Figure 2. Characterization and pathogen-binding efficiency of MNVs. a) Quantitative measurement of the pathogen-binding-related surface receptors on hRBC-MNVs and hWBC-MNVs (n = 3). b) Binding efficiencies of hRBC-MNVs, GYPA-blocked hRBC-MNVs, CR1-blocked hRBC-MNVs, GYPA-and CR1-blocked hRBC-MNVs to methicillin-resistant S. aureus (MRSA), extended-spectrum β-lactamase-positive E. coli (ESBL-EC), RSV, CMV, Zika virus (ZIKV) E protein, HCoV-OC43, and SARS-CoV-2 S protein in human plasma (n = 3). c) Binding efficiencies of hWBC-MNVs, CR1-blocked hWBC-MNVs, CR3-blocked hWBC-MNVs, and CR1-and CR3-blocked hWBC-MNVs to MRSA, ESBL-EC, RSV, CMV, ZIKV E protein, HCoV-OC43, and SARS-CoV-2 S protein in human plasma. d,e) Binding efficiencies of d) hRBC-MNVs and e) hWBC-MNVs to MRSA and ESBL-EC when supplemented with MBL, ficolin (FCN)-1, or C3b in TBS buffer (n = 3). f,g) Binding efficiencies of f) hRBC-MNVs and g) hWBC-MNVs to MRSA and ESBL-EC when supplemented with MBL, FCN-1, or C3b in human blood (n = 3). h,i) Binding efficiency of h) hRBC-MNVs and i) hWBC-MNVs to HCoV-OC43, RSV, CMV, SARS-CoV-2 S protein, and Zika virus (ZIKV) E protein in TBS buffer supplemented with MBL, FCN-1, or C3b. j) Binding efficiency of hWBC-MNVs to SARS-CoV-2 S protein when supplemented with MBL, FCN-1, or anti-SARS-CoV-2 S protein immunoglobulin G (IgG) (n = 3). k) D-glucose depletion in diabetic rat blood by repetitive incubation and magnetic depletion using hRBC-MNVs. l) MRSA spiked in diabetic rat blood was magnetically depleted using hRBC-MNVs. m) Fecal bacterial concentrations in human whole blood were significantly (99.97%) reduced after a single round of magnetic depletion using hRBC-MNVs (n = 3). n) The removal efficiency of SARS-CoV-2 spike protein and their variants (B.1.1.7, B.1351, B.1.617.2 and B.1.1.529) using hWBC-MNVs (n = 3). Data were expressed as means ± SEM. Statistical significance was calculated by a two-tailed Student's t test. *P < 0.05; **P < 0.005; ***P < 0.001; NS, not significant.